eMedicine Specialties > Dermatology > Malignant Neoplasms

Paget Disease, Extramammary

Author: Joseph L Wilde, MD, Chief, Department of Dermatology, Vicenza Army Health Center, Italy
Contributor Information and Disclosures

Updated: Dec 3, 2009

Introduction

Background

Radcliffe Crocker first recognized and reported extramammary Paget disease (EMPD) as a distinct clinical entity in 1889. Extramammary Paget disease is morphologically and histologically identical to mammary Paget disease of the nipple, which James Paget had described 15 years earlier. The primary difference is the anatomic location. Crocker described a patient with erythematous patches on his penis and scrotum. Since he made this distinction, the term extramammary Paget disease is more commonly used to describe the condition in women. This process targets the genital skin, perianal skin, and other cutaneous sites rich in apocrine glands. Extramammary Paget disease is not a common disorder, but it must be considered in the differential diagnosis of patients with chronic genital or perianal dermatitis.

Pathophysiology

Extramammary Paget disease (EMPD) arises as a primary cutaneous adenocarcinoma in most cases. The epidermis becomes infiltrated with neoplastic cells showing glandular differentiation. Tumor cells may originate from apocrine gland ducts or from keratinocytic stem cells.

Approximately 25% of the cases of extramammary Paget disease (range, 9-32%) are associated with an underlying in situ or invasive neoplasm. In all patients, the neoplasm most likely to be associated with extramammary Paget disease is an adnexal apocrine carcinoma. This associated neoplasm probably represents infiltration of the deeper adnexa by epidermal Paget cells. In addition to cutaneous adnexal carcinoma, other associated malignancies include the following: carcinoma of the Bartholin glands, urethra, bladder, vagina, cervix, endometrium, or prostate.
The anatomic location of extramammary Paget disease plays a role in predicting the risk of associated carcinoma. For instance, about 4-7% of patients with genital disease have an associated carcinoma. Perianal disease is associated with underlying colorectal carcinoma in 25-35% of cases.

Rare cases of extramammary Paget disease associated with tumors arising in distant organs without direct epithelial connection to the affected epidermis have been reported. Roy et al reported Paget disease in a retrorectal dermoid cyst.1 No clear evidence supports a causal link between these distant tumors and cutaneous extramammary Paget disease.

Frequency

International

Extramammary Paget disease is a rare condition with only several hundred cases in the world literature.

Mortality/Morbidity

  • The course of extramammary Paget disease may last 10-15 years without evidence of cancer or metastases.
  • In a minority of patients, tumor cells infiltrate the dermis, adnexa, or lymph nodes. Both mortality and morbidity rates are increased in these patients because of the extensive surgical treatment and/or chemotherapy that they need.
  • One study showed a mortality rate of 18% for patients without associated carcinoma and 46% for those with underlying carcinoma.

Race

Extramammary Paget disease is most commonly reported in white patients, but it may occur in other races.

Sex

Women are more commonly affected by extramammary Paget disease than men. The female-to-male ratio was 4.5:1 in one series of 55 patients and 3:1 in another series of 197 patients.2

Age

Extramammary Paget disease most commonly appears in individuals aged 50-60 years.

Clinical

History

Most patients with extramammary Paget disease have only pruritus in the affected area and no other symptoms.

  • Patients with extramammary Paget disease (EMPD) usually present with a nonresolving eczematous lesions in the groin, genitalia, perineum, or perianal area.3
  • The most common symptom of extramammary Paget disease is intense pruritus.
  • Pain and bleeding may occur in longer-standing lesions.

Physical

At clinical examination, extramammary Paget disease (EMPD) may appear as chronic intertrigo or presumed tinea cruris. Extramammary Paget disease may appear eczematous, and it has usually been present for a long time before biopsy is performed to confirm the diagnosis.

  • The genitalia, perineum, axillae, and external auditory canal are rich in apocrine glands; therefore, these are the usual sites of extramammary Paget disease involvement.
  • Early skin changes may be subtle and vary according to location.
  • Initially, only slight erythema, crusting, and increased maceration may be noted.
  • Pruritus commonly leads to prominent excoriations and lichenification.
  • Lesional progression leads to a unilateral sharply marginated plaque with distinct erythema.
  • Superficial erosion or scaling may develop in mature lesions.

Causes

  • The cause of primary extramammary Paget disease (EMPD) is unknown.
  • However, a minority of cases do represent a direct extension of an underlying carcinoma along contiguous epithelium.

More on Paget Disease, Extramammary

Overview: Paget Disease, Extramammary
Differential Diagnoses & Workup: Paget Disease, Extramammary
Treatment & Medication: Paget Disease, Extramammary
Follow-up: Paget Disease, Extramammary
References

References

  1. Roy J, Mirnezami A, Gatt M, Sasapu K, Scott N, Sagar P. A rare case of Paget's disease in a retrorectal dermoid cyst. Colorectal Dis. Nov 2 2009;[Medline].

  2. Chanda JJ. Extramammary Paget's disease: prognosis and relationship to internal malignancy. J Am Acad Dermatol. Dec 1985;13(6):1009-14. [Medline].

  3. Bagby CM, MacLennan GT. Extramammary Paget's disease of the penis and scrotum. J Urol. Dec 2009;182(6):2908-9. [Medline].

  4. Cho SB, Yun M, Lee MG, Chung KY. Variable patterns of positron emission tomography in the assessment of patients with extramammary Paget's disease. J Am Acad Dermatol. Feb 2005;52(2):353-5. [Medline].

  5. Beleznay KM, Levesque MA, Gill S. Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain. Curr Oncol. Sep 2009;16(5):81-3. [Medline].

  6. Sendagorta E, Herranz P, Feito M, et al. Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod - proposal of a therapeutic schedule. J Eur Acad Dermatol Venereol. Oct 15 2009;[Medline].

  7. Takahagi S, Noda H, Kamegashira A, et al. Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol. Aug 2009;36(8):457-61. [Medline].

  8. Appert DL, Otley CC, Phillips PK, Roenigk RK. Role of multiple scouting biopsies before Mohs micrographic surgery for extramammary Paget's disease. Dermatol Surg. Nov 2005;31(11 Pt 1):1417-22. [Medline].

  9. Coldiron BM, Goldsmith BA, Robinson JK. Surgical treatment of extramammary Paget's disease. A report of six cases and a reexamination of Mohs micrographic surgery compared with conventional surgical excision. Cancer. Feb 15 1991;67(4):933-8. [Medline].

  10. Hendi A, Brodland DG, Zitelli JA. Extramammary Paget's disease: surgical treatment with Mohs micrographic surgery. J Am Acad Dermatol. Nov 2004;51(5):767-73. [Medline].

  11. Brainard JA, Hart WR. Proliferative epidermal lesions associated with anogenital Paget's disease. Am J Surg Pathol. Apr 2000;24(4):543-52. [Medline].

  12. Jaworsky C, Miller SJ, Maloney ME. Extramammary Paget's disease. In: Cutaneous Oncology: Pathophysiology, Diagnosis, Management. London, England: Blackwell Science; 1998:789-95.

  13. Kodama S, Kaneko T, Saito M, Yoshiya N, Honma S, Tanaka K. A clinicopathologic study of 30 patients with Paget's disease of the vulva. Gynecol Oncol. Jan 1995;56(1):63-70. [Medline].

  14. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J Clin Pathol. Oct 2000;53(10):742-9. [Medline].

  15. Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC, Milsom JW. Long-term outcome of patients with perianal Paget's disease. Ann Surg Oncol. Sep 1997;4(6):475-80. [Medline].

  16. Murata Y, Kumano K, Tani M. Underpants-pattern erythema: a previously unrecognized cutaneous manifestation of extramammary Paget's disease of the genitalia with advanced metastatic spread. J Am Acad Dermatol. Jun 1999;40(6 Pt 1):949-56. [Medline].

  17. Parker LP, Parker JR, Bodurka-Bevers D, et al. Paget's disease of the vulva: pathology, pattern of involvement, and prognosis. Gynecol Oncol. Apr 2000;77(1):183-9. [Medline].

Further Reading

Keywords

extramammary Paget disease, extramammary Paget’s disease, EMPD, intraepidermal adenocarcinoma, mammary Paget disease, mammary Paget's disease, primary cutaneous adenocarcinoma

Contributor Information and Disclosures

Author

Joseph L Wilde, MD, Chief, Department of Dermatology, Vicenza Army Health Center, Italy
Joseph L Wilde, MD is a member of the following medical societies: American College of Mohs Micrographic Surgery and Cutaneous Oncology
Disclosure: Nothing to disclose.

Medical Editor

Marjan Garmyn, MD, PhD, Professor, Faculty of Medicine, Katholieke Universiteit Leuven, Belgium; Chair and Adjunct Head, Department of Dermatology, University of Leuven, Belgium
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Mary Farley, MD, Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center
Disclosure: Nothing to disclose.

CME Editor

Catherine M Quirk, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania
Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.